CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Tremblay, France

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

    Phase

    4

    Span

    216 weeks

    Sponsor

    Insel Gruppe AG, University Hospital Bern

    Christchurch

    Recruiting

  • A Study to Evaluate KRIYA-825 (VV-14295) in Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration

    Phase

    1/2

    Span

    146 weeks

    Sponsor

    Kriya Therapeutics, Inc.

    Christchurch

    Recruiting

  • Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

    This is a Phase 2a efficacy and safety study of intravenous EVO301 in adults with moderate to severe atopic dermatitis.

    Phase

    2

    Span

    51 weeks

    Sponsor

    Evommune, Inc.

    Christchurch

    Recruiting

  • Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

    Phase

    1

    Span

    94 weeks

    Sponsor

    Arrowhead Pharmaceuticals

    Christchurch

    Recruiting

  • A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

    Phase

    1/2

    Span

    103 weeks

    Sponsor

    Korro Bio, Inc.

    Christchurch

    Recruiting

    Healthy Volunteers

  • A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

    Phase

    1

    Span

    56 weeks

    Sponsor

    Assembly Biosciences

    Christchurch

    Recruiting

    Healthy Volunteers

  • A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

    This study will enroll approximately 180 participants and eligible patients will be randomized to one of 3 treatment arms: - Arm 1: Treatment Group 1: Placebo delivered subcutaneously (SC) every 2 weeks (Q2W) for 24 weeks - Arm 2: Treatment Group 2: TX000045 SC at Dose A Q2W for 24 weeks - Arm 3: Treatment Group 3: TX000045 SC at Dose B Q2W alternating with Placebo Q2W for 24 weeks

    Phase

    2

    Span

    111 weeks

    Sponsor

    Tectonic Therapeutic

    Christchurch

    Recruiting

  • A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

    Phase

    1

    Span

    100 weeks

    Sponsor

    Dren Bio

    Christchurch

    Recruiting

  • A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants

    This is a single-dose escalation study of HB0056 to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of HB0056.

    Phase

    1

    Span

    46 weeks

    Sponsor

    Shanghai Huaota Biopharmaceutical Co., Ltd.

    Christchurch

    Recruiting

    Healthy Volunteers

  • A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)

    Phase

    3

    Span

    170 weeks

    Sponsor

    Annexon, Inc.

    Christchurch, Canterbury

    Recruiting

1-10 of 123
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information